| CEO Name | Marc Prikazsky |
| Nationality | France |
| Net Worth Estimation | $30 million |
Marc Prikazsky, CEO of Ceva Sante Animale, holds significant equity in the privately held global animal health company, which has driven his estimated net worth to around $30 million due to its strong financial growth and valuation in the veterinary sector. His leadership and long tenure have further increased his share value and overall wealth through company expansion and profitability.
Marc Prikazsky, CEO of Ceva Sante Animale, has an estimated net worth of $30,000,000, which is 42.9% of the maximum and 2,900% of the minimum in the veterinary business category. His net worth places him solidly in the mid-to-upper range compared to industry peers.
Business Category: Veterinary
Minimum Net Worth (estimation): 1000000 USD
Maximum Net Worth (estimation): 70000000 USD
Marc Prikazsky Performance in Ceva Santé Animale
Marc Prikazsky, CEO of Ceva Sante Animale, demonstrates strategic leadership and data-driven decision-making, focusing on innovation and global market expansion. Under his guidance, Ceva Sante Animale has enhanced its performance through optimized operational efficiency and strengthened R&D investment in animal health products. His impact includes significant revenue growth, increased market share, and a solidified position as a key player in the global animal health industry.
Latest News
Ceva Sante Animale's Capital Restructuring and Leadership by CEO Marc Prikazsky
Ceva Sante Animale, the world's fifth-largest animal health company, restructured its capital in March 2025 to accelerate growth, maintaining majority voting control by CEO Dr. Marc Prikazsky, who has led the company since 2009. Ceva is headquartered in Libourne, France, employs 7,000 people worldwide, and focuses on veterinary pharmaceuticals, vaccines, and animal wellness products, with international presence across 47 countries.
Source: http://presse.avril.com/ceva-animal-health-renews-its-shareholding-structure-with-all-its-long-standing-partners-and-opens-its-capital-to-merieux-institute-and-archimed-to-accelerate-its-growth/